Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use
  • USA - English


News provided by

Wright & Schulte LLC

Nov 22, 2014, 04:00 ET

Share this article

Share toX

Share this article

Share toX

Women Files Xarelto Lawsuit Alleging Blood Thinner Causes Uncontrolled Bleeding
Women Files Xarelto Lawsuit Alleging Blood Thinner Causes Uncontrolled Bleeding
Youtube
Youtube

If you believe you have suffered internal bleeding due to Xarelto contact the attorneys at Wright & Schulte LLC For a Free legal consult buy calling 1-800-399-0795 or visit www.yourlegalhelp.com or call

Post this

Columbus, OH (PRWEB) November 22, 2014 -- A Xarelto lawsuit has been filed on behalf of a 72-year-old New York woman who is seeking $10 million in damages from the makers and marketers of the Xarelto prescription blood thinner. According to the lawsuit, the woman began using Xarelto in March 2012 and used it through July 2012. The woman alleges in her lawsuit she suffered life-threatening bleeding in July 2012 and as a result, sustained severe and permanent personal injuries, pain, suffering and emotional distress. The lawsuit purports that the woman’s injuries are due to the fact that the defendants, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and Bayer HealthCare, knew or should have known that unreasonably dangerous side-effects were associated with Xarelto yet they continued to manufacture, distribute and market the blood thinner. According to the lawsuit, the woman wants to be compensated because she will need lifelong medical treatment, monitoring and medication as a result of using Xarelto. The lawsuit was filed in the U.S. District Court, Eastern District of New York. (1:14-cv-05133-FB-RM)

As Xarelto lawsuit filings continue across the country, court documents indicate that plaintiffs involved in six Xarelto lawsuits have asked the U.S. Judicial Panel on Multidistrict Litigation (JPML) to transfer all federally filed Xarelto lawsuits and consolidate them in the U.S. District Court, Southern District of Illinois. The JPML has scheduled oral arguments on the matter for December 4, 2014, at the U.S. District Court, District of South Carolina in Charleston. The plaintiffs’ motion states that the Xarelto bleeding side-effects complaints all have common allegations of patients who were prescribed the blood thinner medication experienced uncontrolled bleeding which in some instances, resulted in their death. The Xarelto complaints also contend that the defendants failed to warn patients and their doctors that there is no antidote for Xarelto should serious bleeding occur and there is a chance for the patient to suffer life-threatening effects as a result. In its response to the plaintiffs’ motion to consolidate Xarelto lawsuits, Janssen asked the JPML not to establish multidistrict litigation for only an estimated 30 lawsuits, the number of Xarelto complaints filed as of October 31, 2014, but to allow an informal coordination of the cases between attorneys for plaintiffs and defendants. (In Re: Xarelto Products Liability Litigation, MDL No. 2592, JPML)
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm, November 2, 2012]

Xarelto (generically known as rivaroxaban) is an oral anticoagulant that was approved by the U.S. Food and Drug Administration (FDA) to treat deep vein thrombosis and pulmonary embolism. Xarelto along with Pradaxa (dabigatran), and Eliquis (apixaban) are three new FDA-approved blood thinners that have joined warfarin (Coumadin, Jantoven), a blood thinner that has been on the U.S. market for 60 years. According to the FDA, warfarin uses vitamin K to reverse the effects of warfarin should serious bleeding occur in a patient. Unlike warfarin, there are no reversal agents for the new blood thinners should significant bleeding occur, the federal agency says.
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]

The Xarelto blood thinner was first approved by the FDA in July 2011 to reduce the risk of blood clots in patients who had knee or hip replacement surgery. In November 2011, the FDA approved Xarelto to reduce the risk of stroke and blood clots in patients with atrial fibrillation (irregular heart rhythms). In June 2013, the FDA issued a warning letter to Johnson & Johnson regarding a print advertisement for Xarelto, that was submitted on behalf of Janssen Pharmaceuticals, Inc. The FDA called the print ad “false or misleading” because it minimized the risks associated with Xarelto. Additionally, the FDA letter noted that the ad made a misleading claim by saying that there are no dosage adjustments for Xarelto when in fact, the product label for Xarelto mentioned that patients with renal impairment may need to have their dosage adjusted while using Xarelto. The FDA letter also mentioned that the most common adverse reactions with Xarelto were bleeding complications.
[fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation
/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetters
toPharmaceuticalCompanies/UCM357833.pdf, June 6, 2013]

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today for a FREE Xarelto bleeding lawsuit evalution through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Richard Schulte, Wright & Schulte LLC, http://yourlegalhelp.com/, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.